Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

Phase 2CompletedNCT01557010

Daewoong Pharmaceutical Co. LTD.140 enrolled

Overview

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

140

Conditions

Postherpetic Neuralgia

Interventions

DWP05195DRUG

Tablets, oral administration, 100mg

DWP05195DRUG

Tablets, oral administration, 200mg

DWP05195DRUG

Tablets, oral administration, 300mg

Control

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or Female subjects aged 20 to 80 years * Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN). * Subjects must have pain present for \> 3 months after healing of the acute herpes zoster skin rash. Exclusion Criteria: * Other severe pain that may potentially confound pain assessment. * Subjects with symptoms of neuropathic pain applied Medical Equipment * Within 2 years: Subjects were diagnosed with cancer

Outcomes

Primary Outcomes

Endpoint change from the baseline after administered 8 weeks mean pain score based on the Numerical pain Rating Scale(NPRS) from the subject's daily pain diary

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.